;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Marinus sets IPO terms

    Marinus Pharmaceuticals Inc. (New Haven, Conn.) said it plans to sell 4 million shares at $12-$14 in an IPO on NASDAQ. At the $13 midpoint, the company would raise $52 million and be valued at $159 million. Marinus …

    Published on 7/18/2014
  • FINANCIAL NEWS: New Science Ventures planning $100 million third fund

    New Science Ventures is looking to raise $100 million for its third fund, according to an SEC filing. The firm, which declined to comment, invests in life sciences and IT companies in the U.S., Europe, India and China. …

    Published on 7/18/2014
  • FINANCIAL NEWS: Sage jumps 67% in trading debut

    Neurology company Sage Therapeutics Inc. (NASDAQ:SAGE) gained $12.10 (67%) to $30.10 on its first day of trading Friday after raising $90 million through the sale of 5 million shares at $18 in an IPO. The price values …

    Published on 7/18/2014
  • FINANCIAL NEWS: StemCells raises $20 million in private placement

    StemCells Inc. (NASDAQ:STEM) raised $20 million through the sale of 11.3 million units at $1.77 in a private placement to two institutional investors. Each unit comprises a share and a 13-month warrant to purchase 0.85 …

    Published on 7/18/2014
  • FINANCIAL NEWS: CymaBay amends follow-on

    CymaBay Therapeutics Inc. (NASDAQ:CBAY) said it now plans to sell 3.5 million shares in a follow-on. If sold at the company's close of $6.03 on Wednesday, before CymaBay announced the amendment, the company would raise…

    Published on 7/17/2014
  • FINANCIAL NEWS: Edico raises $10 million in A round

    Edico Genome Inc. (La Jolla, Calif.) raised $10 million in a series A round led by Qualcomm Ventures. Axon Ventures and Gregory Lucier also participated. Edico is developing its Dragen Bio-IT processor, which reduces …

    Published on 7/17/2014
  • FINANCIAL NEWS: Novartis misses Street's sales estimates

    Novartis AG (NYSE:NVS; SIX:NOVN) on Thursday reported $14.6 billion in net sales in 2Q14, missing the Street's estimate of $14.8 billion, but up 2% from 2Q13. The pharma also reported $1.34 core EPS, up from $1.29 in …

    Published on 7/17/2014
  • FINANCIAL NEWS: Roka raises $60 million in IPO

    Molecular diagnostics play Roka Bioscience Inc. (NASDAQ:ROKA) raised $60 million through the sale of 5 million shares at $12 in an IPO. The price values the company at $211.6 million. Earlier this month, the company …

    Published on 7/17/2014
  • FINANCIAL NEWS: Sage, Pfenex amend IPOs

    Neurology company Sage Therapeutics Inc. (Cambridge, Mass.) amended an IPO on NASDAQ, while biosimilar play Pfenex Inc. (San Diego, Calif.) amended an NYSE IPO. Sage now plans to sell 5 million shares at $17-$18. At the…

    Published on 7/17/2014
  • FINANCIAL NEWS: Zosano sets IPO terms

    Zosano Pharma Corp. (Fremont, Calif.) amended its IPO on NASDAQ and now plans to sell 6.4 million shares at $10-$12. At the $11 midpoint, the company would raise $70.4 million and be valued at $133.7 million. Zosano …

    Published on 7/17/2014
  • FINANCIAL NEWS: Genocea pulls follow-on

    Infectious disease company Genocea Biosciences Inc. (NASDAQ:GNCA) withdrew a proposed follow-on, citing market conditions. The company said it "remains well capitalized" and said its cash should provide runway through …

    Published on 7/16/2014
  • FINANCIAL NEWS: immatics raises EUR 22 million to close out D round

    immatics biotechnologies GmbH (Tuebingen, Germany) raised EUR 22 million ($30 million) in the final tranche of a series D round, bringing the total raised in the round to EUR 34 million ($46.3 million). The cancer …

    Published on 7/16/2014
  • FINANCIAL NEWS: Medigene raises EUR 15.9 million

    Medigene AG (Xetra:MDG) raised EUR 15.9 million ($21.7 million) in an offering comprising EUR 15.1 million ($20.5 million) through the sale of 3 million shares at EUR 5 and EUR 818,658 ($1.1 million) in zero-coupon …

    Published on 7/16/2014
  • FINANCIAL NEWS: Ergomed up slightly in debut

    CRO Ergomed Clinical Research Ltd. (LSE:ERGO) gained 2.50p to 162.50p on its first day of trading Tuesday. On July 9, the company raised L11 million ($18.7 million) through the sale of 6.9 million shares at 160p in its …

    Published on 7/15/2014
  • FINANCIAL NEWS: Innocoll, Bio Blast set IPO ranges

    Innocoll GmbH (Athlone, Ireland) and Bio Blast Pharma Ltd. (Tel Aviv, Israel) both set ranges for proposed IPOs on NASDAQ. Innocoll plans to sell 5.4 million ADSs at $13-$15. At the $14 midpoint, Innocoll would raise $…

    Published on 7/15/2014
  • FINANCIAL NEWS: J&J's 2Q14 earnings top Street

    Johnson & Johnson (NYSE:JNJ) reported 2Q14 financial results that beat the Street and posted double-digit growth in worldwide pharmaceutical sales. Global pharma sales for the quarter rose 21% to $8.5 billion from $7 …

    Published on 7/15/2014
  • FINANCIAL NEWS: RestorGenex raises $35.6 million

    RestorGenex Corp. (OTCQB:RESX) raised $35.6 million through the sale of 8.9 million units at $4 in a private placement to institutional investors, including Ally Bridge Group, and accredited investors. Each unit …

    Published on 7/15/2014
  • FINANCIAL NEWS: Tribute raises $27.9M in follow-on

    Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF; TSX-V:TRX) raised C$30 million ($27.9 million) through the sale of 42.9 million units at C$0.70 in a follow-on underwritten by Dundee and Mackie Research Capital Corp. …

    Published on 7/15/2014
  • FINANCIAL NEWS: Applied Genetic planning follow-on

    Rare ophthalmic disease company Applied Genetic Technologies Corp. (NASDAQ:AGTC) proposed to sell 2 million shares in a follow-on. If sold at the company's close of $19.07 on Friday, before Applied Genetic's company …

    Published on 7/14/2014
  • FINANCIAL NEWS: Genocea sets share number for follow-on

    Infectious disease company Genocea Biosciences Inc. (NASDAQ:GNCA) said it plans to sell 3.4 million shares in a follow-on underwritten by Citigroup; Cowen; Stifel; and Needham. Genocea proposed to raise up to $60 …

    Published on 7/14/2014
  • FINANCIAL NEWS: Immune Design sets IPO range

    Cancer immunotherapy company Immune Design Corp. (Seattle, Wash.) amended its IPO on NASDAQ and now plans to sell 4.7 million shares at $12-$14. At the $13 midpoint, the company would raise $60.5 million and be valued …

    Published on 7/14/2014
  • FINANCIAL NEWS: Auspex raises $60.6 million in follow-on

    Rare neurology disease play Auspex Pharmaceuticals Inc. (NASDAQ:ASPX) raised $60.6 million through the sale of 3.2 million shares at $19.25 in a follow-on underwritten by Stifel; BMO Capital Markets; Baird; William …

    Published on 7/11/2014
  • FINANCIAL NEWS: Ocular sets IPO range

    Ocular Therapeutix Inc. (Bedford, Mass.) amended its IPO on NASDAQ and now plans to sell 5 million shares at $14-$16. At the $15 midpoint, the company would raise $75 million and be valued at $308.5 million. Ocular …

    Published on 7/11/2014
  • FINANCIAL NEWS: Otonomy files for IPO

    Otonomy Inc. (San Diego, Calif.) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by JPMorgan; BofA Merrill Lynch; Piper Jaffray; and Sanford C. Bernstein. Next half, the company plans to submit an …

    Published on 7/11/2014
  • FINANCIAL NEWS: Sofinnova seeking $500 million for new fund

    Sofinnova Ventures is looking to raise $500 million for a ninth fund, according to an SEC filing. The firm raised $440 million for its eighth fund and first life sciences-only fund in 2011. Sofinnova's portfolio …

    Published on 7/11/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993